Navigation Links
Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation
Date:11/11/2008

New post-hoc analysis from ATHENA Study showed that Multaq(R) on top of standard therapy significantly decreased the total number of hospital days by 28% in patients with atrial fibrillation or flutter

NEW ORLEANS, Nov. 11 /PRNewswire-FirstCall/ -- New data from the landmark ATHENA trial showed that dronedarone significantly reduced the incidence and total duration of hospital stays among patients with atrial fibrillation/atrial flutter (AF/AFL). This post-hoc analysis was presented at the 2008 American Heart Association Scientific Sessions in New Orleans, Louisiana.

In this new analysis, dronedarone significantly reduced the total number of hospital days by 28 percent (p<0.001) versus placebo (9,995 days vs. 13,986 days), and decreased by 35 percent (p<0.001) the total length of time spent in hospital for cardiovascular reasons (5,875 days vs. 9,073 days).

In addition to the demonstrated reduction of AF-related hospitalization by 37 percent (p<0.001), dronedarone reduced the incidence of first non-AF related CV hospitalization (e.g. myocardial infarction or unstable angina by 14 percent (p=0.016). Dronedarone did not increase the incidence of non-cardiovascular hospitalizations in comparison to the placebo arm.

"The incidence of AF-related hospital admissions has dramatically increased in recent years, and therapeutic solutions to reduce this burden are needed," said Dr. Christian Torp-Pedersen from the Gentofte University Hospital, Copenhagen, Denmark and a member of the steering committee of the ATHENA study. "These new ATHENA data showed that, for the first time, an anti-arrhythmic drug significantly and consistently reduced hospitalization incidence and duration, which led to a substantial reduction of total hospitalization burden in this patient population."

A second post-hoc analysis from ATHENA also presented during the AHA, confirmed the rhythm and rate controlling properties of dronedarone, previously demonstrated
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
2. ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
3. ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
4. Multaq(R) (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation
5. American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
6. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
7. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
8. New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
9. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
10. Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture
11. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Revenue and earnings above the previous ... development In the past 2013/14 fiscal year (ended ... to EUR 4.287 billion (last year: EUR 4.190 billion) despite ... EUR 360 million. "Overall, 2013/14 was a successful fiscal year ... President and CEO of Carl Zeiss AG. "Thanks to our ...
(Date:12/17/2014)... With advancements in neurological and functional ... seeing new growth, according to Kalorama Information. Though ... the majority of market volume, newer 3T systems ... are creating opportunities for more sophisticated applications. The medical ... a rate of 4%, with world market revenues ...
(Date:12/17/2014)... Dec. 17, 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") ... and Trademark Office (USPTO) has issued a key ... cell-based immunotherapeutic vaccine targeting six tumor antigens that ... US Patent No. 8,871,211, which issued October 28, ... administering a dendritic cell composition comprising peptide epitopes ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... AUGUSTINE, Fla., Aug. 10, 2011 Flagler Hospital ... selected the Sunrise Enterprise ™ suite of clinical ...  In addition to implementing Sunrise within the hospital, Flagler ... Record (EHR) and practice management solution for its ...
... Simbionix USA Corporation, the world,s leading provider of ... and the healthcare industry, is pleased to announce it ... its innovative PROcedure Rehearsal Studio ™ . ... in industry product, allowing clinicians to create patient specific 3D ...
Cached Medicine Technology:Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 2Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 3Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 4Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 5Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 6Patent Granted for Simbionix Procedure Rehearsal Studio™ 2
(Date:12/20/2014)... (PRWEB) December 21, 2014 BambooIndustry.com ... . Recently, the business has announced its bamboo ... buys the best material from certified suppliers, and ... its customers worldwide. In the current promotion, all ... 20% off, when they say they know BambooIndustry.com ...
(Date:12/20/2014)... An improving macroeconomic landscape and a ... Massage Services industry over the five years ... the anticipated 1.0% annualized increase in per capita disposable ... the means to afford additional massages. “While the share ... a given year has declined from 2009 to 2012, ...
(Date:12/20/2014)... The print component of Healthy Aging ... of approximately 160,000 copies and an estimated readership of ... vast social media strategy and across a network of ... digital version of the campaign, click here . ... the ladies of CTV’s The Social. Lainey Lui, ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 The Doctor’s Office ... for the better part of a decade. They’ve treated ... a better, faster healthcare alternative to the Paramus ... announce three new additions to their staff of top-notch board ... Jill Zeiger MD. These new doctors will work ...
(Date:12/20/2014)... (PRWEB) December 20, 2014 Atore, Inc, ... company just launched first birthday focused portal on December ... BIRTHDAY MESSAGE” launched in both US and Japan. , ... MESSAGE : http://merrybirthday.net/message/ , MERRY BIRTHDAY MESSAGE ... birthday around the world. , Features, Choose from thousands ...
Breaking Medicine News(10 mins):Health News:Eco-friendy Bamboo Flooring Manufacturer BambooIndustry.com Introduces Its Bamboo Flooring Promotion for 2015 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Atore, Inc. Releasing the First Birthday Portal 2
... YORK, July 7 As part of its ongoing ... MagnaCare, the region,s recognized leader in innovative healthcare administration ... launch of its new full-service pharmacy benefit management (PBM) ... better solutions for pharmacy benefit management. With costs rising, ...
... July 7 Diplomat Specialty Pharmacy, a leader ... (DTM) announced today that their specialty pharmacy has ... care accrediting organization that establishes quality standards for ... Pharmacy received accreditation for their Chronic Kidney Disease ...
... Darvon, Darvocet have been linked to fatal overdoses ... about the possibility of fatal overdoses led U.S. ... limit the risk of using pain medications containing ... strengthen the labels of propoxyphene-containing products by adding ...
... women more likely to die, but questions remain , TUESDAY, ... cancer outcomes, with black women more likely to die from ... new research shows. , , For a quarter of a ... in certain cancers. The racial disparity "first emerged about 25 ...
... BERLIN, July 7 Ulrich Stroeher, Chairman of the Advisory,Board ... leaving,the general management of the company on 30 September 2009. ... company,s founders and is one of the,intellectual fathers of the ... wealth of experience in this area as,coordinator for projects with ...
... /PRNewswire/ -- The VAP(R) Cholesterol Test recently ... nine steps to a longer life. TRANSCEND: Nine Steps ... Terry Grossman, M.D., and world-renowned futurist Ray Kurzweil, identifies the ... in cardiovascular risk assessment. , , Grossman, the book,s ...
Cached Medicine News:Health News:MagnaCare Answers Need for New Prescription Drug Program 2Health News:Diplomat Specialty Pharmacy: Only Vendor to Receive URAC Accreditation for Both Disease Management and Drug Therapy Management 2Health News:Diplomat Specialty Pharmacy: Only Vendor to Receive URAC Accreditation for Both Disease Management and Drug Therapy Management 3Health News:FDA Mandates Tougher Warnings for Pain Pills 2Health News:New Clues to Race Gap in Breast Cancer Outcomes 2Health News:New Clues to Race Gap in Breast Cancer Outcomes 3Health News:Berlin Heart Announces Restructuring of Management 2Health News:VAP(R) Cholesterol Test Highlighted in Groundbreaking Book on Longevity 2Health News:VAP(R) Cholesterol Test Highlighted in Groundbreaking Book on Longevity 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: